Retrospective analysis assesses BRCA1/2 mutation locations' impact on prognosis in ovarian cancer, indicating no survival differences.
Key Points
Patients with BRCA1 Group A and BRCA2 mutations were often diagnosed with advanced-stage ovarian cancer, indicating a potential link to disease severity.
Despite analyzing 375 patients, survival outcomes did not differ significantly between BRCA1/2 mutational groups over a median follow-up of 89 months.
The study classified BRCA mutations into three groups based on their location to understand their prognostic impact on overall survival and progression-free survival.
These findings suggest that while distinct mutational locations of BRCA1 and BRCA2 exist, they do not correlate with differences in patient survival outcomes.